FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma

Blood. 2012 Jan 26;119(4):1029-31. doi: 10.1182/blood-2011-10-383380. Epub 2011 Dec 5.

Abstract

Women treated at young ages with supradiaphragmatic radiotherapy for Hodgkin lymphoma (HL) have a highly increased risk of breast cancer. For personalized advice and follow-up regimens for patients, information is needed on how the radiotherapy-related risk is affected by other breast cancer risk factors. Genome-wide association studies have identified 14 independently replicated common single nucleotide polymorphisms that influence breast cancer risk. To examine whether these variants contribute to risk of radiation-associated breast cancer in HL, we analyzed 2 independent case-control series, from the United Kingdom and The Netherlands, totaling 693 HL patients, 232 with breast cancer and 461 without. rs1219648, which annotates the FGFR2 gene, was associated with risk in both series (combined per-allele odds ratio = 1.59, 95% confidence interval: 1.26-2.02; P = .000111). These data provide evidence that genetic variation in FGFR2 influences radiation-induced breast cancer risk.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Breast Neoplasms / complications
  • Breast Neoplasms / etiology
  • Breast Neoplasms / genetics*
  • Case-Control Studies
  • Female
  • Genetic Predisposition to Disease
  • Hodgkin Disease / complications
  • Hodgkin Disease / genetics
  • Hodgkin Disease / radiotherapy*
  • Humans
  • Mammary Glands, Human / radiation effects*
  • Middle Aged
  • Netherlands / epidemiology
  • Polymorphism, Single Nucleotide*
  • Precision Medicine
  • Receptor, Fibroblast Growth Factor, Type 2 / genetics*
  • Risk
  • United Kingdom / epidemiology

Substances

  • FGFR2 protein, human
  • Receptor, Fibroblast Growth Factor, Type 2